TOPIC 421: BUILDING THE WORLD'S FIRST CLINICAL OXYGEN IMAGER FOR EFFICIENT CANCER TREATMENT

NIH RePORTER · NIH · N43 · $400,000 · view on reporter.nih.gov ↗

Abstract

2019 Nobel prize in medicine for the discovery of oxygen signaling pathways highlights the importance of oxygenation as a physiologic parameter. Oxygenation plays a key role in cancer development and may affect its aggressiveness. Tumors have a highly heterogeneous oxygen environment which affects the outcome of chemo- and radiation treatment. Hypoxia, or low oxygenation, is an obstacle to successful cancer treatment. The accurate measurement of tissue oxygenation is necessary for oxygen guided radiation therapy (OGRT) that reduces the overall radiation dose. However, currently, clinicians do not have access to a quantitative oxygen imager that can be utilized for cancer treatment. In this Phase I proposal, we will develop a human-size oxygen imaging instrument based on electron paramagnetic resonance oxygen imaging principles. The instrument will be tested with phantoms and a pilot rabbit study for its ability to provide 3D oxygen maps of a leg born VX-2 tumor. The success of this project will bring a translational technology from preclinical research to the clinical domain with a new product in the market, CAELI-9.

Key facts

NIH application ID
10492291
Project number
75N91021C00034-0-9999-1
Recipient
O2M TECHNOLOGIES, LLC
Principal Investigator
MRIGNAYANI KOTECHA
Activity code
N43
Funding institute
NIH
Fiscal year
2021
Award amount
$400,000
Award type
Project period
2021-09-16 → 2022-06-15